吡嗪酰胺致肺结核合并糖尿病患者高尿酸血症临床分析

Clinical analysis of hyperuricemia induced by Pyrazinamide in treatment of tuberculosis patients with diabetes

目的了解吡嗪酰胺对肺结核合并糖尿病患者高尿酸血症发生率及严重程度。方法 118例肺结核合并糖尿病患者为观察组。选取同期肺结核未合并糖尿病患者118例为对照组。对高尿酸血症发生率、严重程度及相关因素进行对比观察。结果观察两组高尿酸血症发生率有显著差异P<0.05,观察组重度高尿酸血症发生率较对照组明显增高P<0.05,临床症状出现率及症状消失时间均有显著差异<0.05。结论吡嗪酰胺应用于肺结核合并糖尿病患者时高尿酸血症发生率高、且重度高尿酸血症发生率亦高,发生时间早,关节症状出现率高、症状消失时间长。提示临床上对肺结核合并糖尿病患者要注意血尿酸变化及临床症状变化,以便及时处理,避免严重并发症发生。

Objective To understand the incidence and severity of hyperurieemia induced by Pyrasinamide in treatment of tuber- culosis patients with diabetes. Methods 118 tuberculosis patients with diabetes mellitus for the observation group, and 118 tuberculosis patients without diabetes mellitus were as the control group. The incidence and severity of hyperurieemia, and the related factors were ob- served. Results The rate of hyperurieemia in observation group was significantly higher compared with the control group （ P 〈 0. 05 ） , and rate of severe hyperurieemia in observation group was significantly higher compared with the control group （P 〈 0. 05 ）. There were signifi- cant differences in rate of appearance and disappearance in clinical symptoms （ P 〈 0.05 ）. Conclusion The incidence and severity of hyperurieemia induced by Pyrazinamide in treatment of tuberculosis patients with diabetes are high, and the clinical symptoms appear early and disappear lately, which suggests hyperuricemia induced by Pyrazinamide in treatment of tuberculosis patients with diabetes should be observed to avoid complications.